Your Health, We Care
Release date: 2024-08-07 17:44:23 Recommended: 135
Capmatinib is an oral MET inhibitor that received Breakthrough Therapy Designation, Orphan Drug Designation, Accelerated Approval, and Priority Review from the United States FDA for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harboring MET14 skipping mutations.
Patients and doctors should pay attention to the dosage of the drug, which is organized according to the drug instructions as follows:
400 mg orally twice daily, before and after meals, swallow whole, and do not need to be retaken after missing a dose or vomiting.
Interstitial lung disease (ILD)/pneumonitis
Regardless of severity, the drug needs to be permanently discontinued.
ALT and/or AST are elevated
Grade 3: Suspend the drug and resume the original dose if liver function returns to normal within 7 days.
Grade 4 or with elevated total bilirubin (no cholestasis or hemolysis): Permanently discontinued.
Total bilirubin alone rises to grade 2 or above: the drug is suspended and recovery is observed, and the decision is to resume the original dose, reduce the dose, or permanently discontinue the drug according to the recovery.
Other adverse reactions
Grade 2: Continue on the current dose and discontinue if the patient is unable to tolerate symptoms.
Grade 3: Suspend medication, and resume after symptoms are relieved according to the instructions or according to the doctor's instructions.
Grade 4: Permanent discontinuation.
With the approval of capmatinib in China, more and more patients are concerned about the precautions for the use of the drug, and according to the drug instructions, patients need to pay attention to the following aspects during use:
Capmatinib can cause serious harm to the fetus and baby, and it is recommended that pregnant and lactating women should not use the drug. Patients should consult their doctor immediately if they are planning to become pregnant or if they are pregnant while using capmatinib. Breastfeeding women should stop breastfeeding during treatment to avoid potential health risks to their babies from the drug through breast milk.
Capmatinib may have adverse effects on the liver, leading to impaired liver function; Liver function tests should be performed regularly during the use of capmatinib, and by monitoring liver enzyme levels and other relevant indicators, doctors can detect and treat possible liver function abnormalities in time and prevent the occurrence of severe liver damage.
[Warm Tips] Patients should actively communicate with their doctors about their drug feelings, physical reactions, and changes in their condition; Follow your doctor's medication instructions and take your medication on time and in the right amount.
